van Gils Annabelle L, van Dijk Charlotte E, Koullali Bouchra, Lugthart Malou A, Bet Bo B, van Zijl Maud D, van der Weide Marijke C, Knol H Marieke, Martinez de Tejada Begoña, Gordijn Sanne J, van den Akker Eline S A, Sueters Marieke, de Boer Marjon A, Hermsen Brenda B J, de Mooij Yolanda M, de Weerd Sabina, van Baal Wilhelmina M, van Hoorn Marion E, Oudijk Martijn A, Kazemier Brenda M, Mol Ben Willem J, Pajkrt Eva
Department of Obstetrics and Gynaecology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
Amsterdam Reproduction and Development Research Institute, Amsterdam, the Netherlands.
EClinicalMedicine. 2024 Nov 25;78:102945. doi: 10.1016/j.eclinm.2024.102945. eCollection 2024 Dec.
Previous spontaneous preterm birth (sPTB) is a strong risk indicator for recurrent preterm birth (PTB). Cervical cerclage is an accepted intervention to prevent recurrent PTB in high risk patients. Cervical pessary might be a less invasive alternative. The objective of this study is to determine whether a cervical pessary is non-inferior to cerclage in the prevention of recurrent PTB.
We performed an international, open-label, non-inferiority, randomised controlled trial in 21 hospitals between March 2014 and December 2022. We included singleton pregnancies with an indication for cerclage based on either multiple previous sPTBs <34 weeks or with a previous sPTB <34 weeks and an asymptomatic mid-trimester short cervix (≤25 mm). Randomisation was 1:1, stratified by centre and indication, to cervical pessary or vaginal cerclage. Primary outcome was PTB <32 weeks. Secondary outcomes included (s)PTB rates, obstetric, and maternal outcomes and a composite of adverse perinatal outcomes including perinatal mortality and severe neonatal morbidity. Analysis was by intention-to-treat. Treatment effect was expressed as relative risk (RR), absolute risk difference (aRD) and 95% confidence intervals (CI). Sample size was calculated at 400 participants with a non-inferiority margin for pessary of 10%, meaning that non-inferiority is proven if the upper limit of the CI of the risk difference is <10%. Trial registration at ICTRP: NL-OMON26958.
We randomised 261 participants to pessary (n = 133) or cerclage (n = 128). After the third interim analysis (n = 228 participants), recruitment was halted due to safety concerns and the apparent challenge in establishing non-inferiority of pessary treatment. PTB <32 weeks occurred in 44/130 cases after pessary vs 30/125 cases after cerclage (33.8% vs 24.0% aRR 1.4, 95% CI 0.95-2.1, p = 0.09, aRD 9.8% 95% CI -1.2 to 20.9). The composite of adverse perinatal outcomes occurred in 42 cases after pessary compared to 29 cases in cerclage (32.2% vs 23.2%; RR 1.4 95% CI 0.93-2.1 p = 0.1) and consisted mainly of perinatal death (22.3% vs 14.4% RR 1.5 95% CI 0.9-2.6 p = 0.1).
Non-inferiority of cervical pessary compared to cerclage in preventing recurrent PTB <32 weeks was not proven. Cerclage is the recommended treatment.
ZonMw (#837002406), a Dutch Organisation for Health Research and Development.
既往自发性早产(sPTB)是复发性早产(PTB)的一个强有力的风险指标。宫颈环扎术是预防高危患者复发性PTB的一种公认的干预措施。宫颈托可能是一种侵入性较小的替代方法。本研究的目的是确定宫颈托在预防复发性PTB方面是否不劣于环扎术。
我们在2014年3月至2022年12月期间于21家医院进行了一项国际、开放标签、非劣效性随机对照试验。我们纳入了单胎妊娠,这些妊娠基于既往多次<34周的sPTB或既往<34周的sPTB且孕中期无症状宫颈短(≤25mm)而有环扎术指征。随机分组比例为1:1,按中心和指征分层,分为宫颈托组或阴道环扎术组。主要结局是<32周的PTB。次要结局包括(s)PTB发生率、产科和母体结局以及包括围产期死亡率和严重新生儿发病率在内的不良围产期结局的综合指标。分析采用意向性分析。治疗效果以相对风险(RR)、绝对风险差(aRD)和95%置信区间(CI)表示。样本量计算为400名参与者,宫颈托的非劣效界值为10%,这意味着如果风险差的CI上限<10%,则证明非劣效。在国际临床试验注册平台(ICTRP)的试验注册号为:NL-OMON26958。
我们将261名参与者随机分为宫颈托组(n = 133)或环扎术组(n = 128)。在第三次中期分析(n = 228名参与者)后,由于安全问题以及确定宫颈托治疗的非劣效性存在明显挑战,招募工作停止。宫颈托组130例中有44例发生<32周的PTB,环扎术组125例中有30例发生(33.8%对24.0%,aRR 1.4,95%CI 0.95 - 2.1,p = 0.09,aRD 9.8%,95%CI -1.2至20.9)。宫颈托组有42例出现不良围产期结局综合指标,环扎术组为29例(32.2%对23.2%;RR 1.4,95%CI 0.93 - 2.1,p = 0.1),主要包括围产期死亡(22.3%对14.4%,RR 1.5,95%CI 0.9 - 2.6,p = 0.1)。
未证实宫颈托在预防<32周复发性PTB方面不劣于环扎术。环扎术是推荐的治疗方法。
荷兰卫生研究与发展组织ZonMw(#837002406)。